GM1

GM1 gangliosidosis is a rare inherited disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. The condition may be classified into three major types based on the general age that signs and symptoms first appear: Type I (infantile), Type II (late infantile and juvenile), and Type III (adult). The different types of GM1 gangliosidosis constitute a continuum of the same disease. The types are distinguished by the severity of their symptoms and the age at which symptoms first appear.

Signs and Symptoms

The signs and symptoms of GM1 gangliosidosis are caused by a deficiency of the enzyme beta-galactosidase, which results in the accumulation of certain fats and sugars inside nerve cells, leading to severe neurological problems.

Type I

Type I, also known as the infantile form, is the most severe type of GM1 gangliosidosis. Infants with this type typically appear normal until they are 3 to 6 months old, when their development slows and muscles used for movement weaken. Affected infants may also have an exaggerated startle reaction to loud noises.

Type II

Type II, also known as the late infantile/juvenile form, is characterized by onset between ages 1 and 5. The symptoms are similar to those of Type I, but progress at a slower rate.

Type III

Type III, also known as the adult or chronic form, is the mildest and least common form. The age of onset varies widely, but symptoms often first appear during adolescence.

Causes

GM1 gangliosidosis is caused by mutations in the GLB1 gene. This gene provides instructions for making an enzyme called beta-galactosidase, which breaks down substances in the body called gangliosides. Gangliosides are fats that are important for the normal function of nerve cells in the brain.

Diagnosis

Diagnosis of GM1 gangliosidosis is based on a clinical examination, confirmed by laboratory testing. This testing can include urine tests, skin biopsy, and genetic testing.

Treatment

There is currently no cure for GM1 gangliosidosis, and treatment is symptomatic and supportive. Physical therapy may help to relieve some of the symptoms. Anticonvulsant medicines may be used to control seizures.

Prognosis

The prognosis for individuals with GM1 gangliosidosis varies but is typically poor. The disease is usually fatal in early childhood, but individuals with the Type II or III form may live into adolescence or adulthood.

Epidemiology

GM1 gangliosidosis affects males and females in equal numbers. The exact incidence is unknown, but the disease is considered very rare.

See Also

• Lysosomal storage disease
• Tay-Sachs disease
• Sandhoff disease

References

GM1 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia